Evidence map›Paper›PMID 35922702›Full record

ArticleInternational urology and nephrology2022

Verapamil inhibited the development of ureteral stricture by blocking CaMK II-mediated STAT3 and Smad3/JunD pathways.

Zhibiao Qing, Wuxiong Yuan, Jiansong Wang, Wei Song, Jianjun Luo, Xuecheng Wu, Qiang Lu, Yuanwei Li, Mingqiang Zeng

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zhibiao QingDepartment of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61, Jiefang Road, Changsha, 410005, Hunan province, People's Republic of China.
Wuxiong YuanDepartment of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61, Jiefang Road, Changsha, 410005, Hunan province, People's Republic of China.
Jiansong WangDepartment of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61, Jiefang Road, Changsha, 410005, Hunan province, People's Republic of China.
Wei SongDepartment of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61, Jiefang Road, Changsha, 410005, Hunan province, People's Republic of China.
Jianjun LuoDepartment of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61, Jiefang Road, Changsha, 410005, Hunan province, People's Republic of China.
Xuecheng WuDepartment of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61, Jiefang Road, Changsha, 410005, Hunan province, People's Republic of China.
Qiang LuDepartment of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61, Jiefang Road, Changsha, 410005, Hunan province, People's Republic of China.
Yuanwei LiDepartment of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61, Jiefang Road, Changsha, 410005, Hunan province, People's Republic of China.
Mingqiang ZengDepartment of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61, Jiefang Road, Changsha, 410005, Hunan province, People's Republic of China. hnnu_zmq@hunnu.edu.cn.
Hunan Normal University · CNHunan Provincial People's Hospital · CN

Funding

Doctoral Fund Project of Hunan Provincial People's Hospital BSJJ202114the Research Project from Hunan Provincial Health Commission 202104051787
6 · The paper itself

Abstract

backgroundUreteral stricture (US) is a fibrotic process that leads to urinary tract obstruction and even kidney damage, with the characteristic of reduced extracellular matrix (ECM) degradation and increased collagen synthesis. Verapamil, as a calcium channel blocker, was reported to prevent scar formation. Our work aimed to investigate the biological effects and mechanism of verapamil in US.

methodsFibroblasts were subjected to transforming growth factor-beta 1 (TGF-β1) to stimulate collagen synthesis, and the messenger ribonucleic acid (mRNA) and protein expressions in fibroblasts were assessed using quantitative real-time polymerase chain reaction (qRT-PCR) and western blot. The location of phosphorylation-signal transducer and activator of transcription 3 (p-STAT3) and Jund proto-oncogene subunit (JunD) in fibroblasts were determined by immunofluorescence (IF). The binding relationship between signal transducer and activator of transcription 3 (STAT3) and collagen type I alpha1 (COL1A1)/collagen type III alpha 1 chain (COL3A1) and the binding relationship between JunD and tissue inhibitor of metalloproteinases-1 (TIMP-1) were verified by dual luciferase reporter gene and chromatin Immunoprecipitation (ChIP) assays.

resultsHerein, we found that verapamil could inhibit TGF-β1/Ca2 + ⁄calmodulin-dependent protein kinase II (CaMK II)-mediated STAT3 activation in fibroblasts, and STAT3 inhibition repressed collagen production. In addition, verapamil could inhibit TGF-β1/CaMK II-mediated Mothers against DPP homolog 3 (Smad3)/JunD pathway activation in fibroblasts, and JunD silencing inhibited TIMP1 (a matrix metalloproteinase inhibitor) expression. Our subsequent experiments revealed that STAT3 bound with COL1A1 promoter and COL3A1 promoter and activated their transcription, and JunD bound with TIMP1 promoter and activated its transcription. Moreover, as expected, STAT3 activation could eliminate the inhibitory effect of verapamil treatment on TGF-β1-induced collagen production in fibroblasts, and JunD overexpression reversed the inhibitory effect of verapamil treatment on TGF-β1-induced TIMP1 expression in fibroblasts.

conclusionVerapamil inhibited collagen production and TIMP-1 expression in US by blocking CaMK II-mediated STAT3 and Smad3/JunD pathways.

Indexed as

Transforming Growth Factor beta1Ureteral ObstructionCalcium-Calmodulin-Dependent Protein Kinase Type 2Calcium Channel BlockersCollagenCollagen Type ICollagen Type IIIConstriction, PathologicFibroblastsHumansLuciferasesMatrix Metalloproteinase InhibitorsProto-Oncogene Proteins c-junRNARNA, MessengerSignal TransductionCalcium-Calmodulin-Dependent Protein Kinase Type 2Calcium Channel BlockersCollagenCollagen Type ICollagen Type IIIJunD protein, humanLuciferasesMatrix Metalloproteinase InhibitorsProto-Oncogene Proteins c-junRNARNA, MessengerSmad3 ProteinSMAD3 protein, humanSTAT3 protein, humanSTAT3 Transcription FactorTissue Inhibitor of Metalloproteinase-1Transforming Growth Factor beta1Transforming Growth FactorsVerapamilCaMK IIFibrosisSmad3/JunDSTAT3Ureteral strictureVerapamil

Identifiers

PMID35922702
OpenAlexW4289653808

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.